ONCOBODY
LIVE

Serial Number

79368861

Owner

LinXis B.V.

Attorney

Roberta S. Bren

Filing Date

Feb 2, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ONCOBODY Trademark

Serial Number: 79368861 • Registration: 7376666

ONCOBODY is a trademark filed by LinXis B.V. on February 2, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

LinXis B.V. (4 trademarks)

Cronenburg 152

Entity Type: 16

Trademark Details

Filing Date

February 2, 2023

Registration Date

May 7, 2024

Published for Opposition

February 20, 2024

Goods & Services

Drug delivery agents in the form of powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biochemical medicines for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of cancer

Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations

In vitro analysis for medical and pharmaceutical use, namely, analysis for medical diagnostic or treatment purposes; in vitro testing for medical and pharmaceutical use, namely, testing for medical diagnostic or treatment purposes; consultancy and information services provided via the Internet relating to pharmaceutical products, namely pharmaceutical [ consultatio ] * consultation *

Pharmaceutical research services; scientific research in the nature of conducting clinical trials for pharmaceuticals for others; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 19, 2025 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 14, 2025 ADCH
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Nov 25, 2024 COC.
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2024 FINO
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 18, 2024 APRE
FINAL DISPOSITION NOTICE SENT TO IB
Nov 4, 2024 FICS
FINAL DISPOSITION PROCESSED
Nov 4, 2024 FIMP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Sep 20, 2024 ADCH
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 7, 2024 FICR
TEAS SECTION 7 REQUEST RECEIVED
May 9, 2024 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 7, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
May 7, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
NOTIFICATION PROCESSED BY IB
Feb 27, 2024 GPNX
PUBLISHED FOR OPPOSITION
Feb 20, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 7, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 7, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 31, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 31, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 27, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 27, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 27, 2023 TROA
REFUSAL PROCESSED BY IB
Nov 28, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 7, 2023 RFCS
REFUSAL PROCESSED BY MPU
Nov 7, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 7, 2023 RFCR
NON-FINAL ACTION WRITTEN
Nov 6, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 1, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
May 9, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 5, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 4, 2023 REPR